Source:http://linkedlifedata.com/resource/pubmed/id/15813849
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2005-4-7
|
| pubmed:abstractText |
Del (9q) is a recurrent cytogenetic abnormality in acute myeloid leukaemia (AML). We report an analysis of 81 patients with del(9q) as a diagnostic karyotypic abnormality entered into the Medical Research Council AML trials 10, 11 and 12. Patients were divided into three groups: (i) Sole del (9q), 21 patients; (ii) Del(9q) in association with t(8;21), 29 patients; (iii) Del(9q) in association with other cytogenetic abnormalities, 31 patients. Sole del(9q) was associated with a characteristic bone marrow phenotype at diagnosis: a single Auer rod was found in all cases examined. There was also an association with erythroid dysplasia (74%) and granylocytic lineage vacuolation (90%). The incidence of all three of these features was significantly higher (P < 0.05) in the sole del(9q) group compared with control cases lacking del(9q). The overall survival (OS) of all 81 patients was compared with a control group of 1738 patients with normal cytogenetics entered in the same trials over the period of investigation. The 5-year OS for patients with del(9q) was 45%, compared with 35% for the control group (P = 0.09). Patients with del(9q) in association with t(8;21) had a 5-year OS of 75%, which was significantly better than the groups with either sole del(9q) (40%) and del(9q) with other abnormalities (26%; P = 0.008). Karyotyping indicated a common area of deletion in the region 9q21-22, which was present in 94% of cases. It is likely that the deletion of single or multiple tumour suppressor genes located in this region may underlie the pathogenesis of del (9q) AML.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0007-1048
|
| pubmed:author |
pubmed-author:BoultwoodJacquelineJ,
pubmed-author:BuckGeorginaG,
pubmed-author:BurnettAlanA,
pubmed-author:ChattersSteveS,
pubmed-author:DalySarahS,
pubmed-author:GoldstoneAnthonyA,
pubmed-author:HarrisonChristineC,
pubmed-author:KusecRajkoR,
pubmed-author:PeniketAndrewA,
pubmed-author:SideLucyL,
pubmed-author:WainscoatJamesJ,
pubmed-author:WalkerHelenH,
pubmed-author:WheatleyKeithK
|
| pubmed:issnType |
Print
|
| pubmed:volume |
129
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
210-20
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:15813849-Acute Disease,
pubmed-meshheading:15813849-Adolescent,
pubmed-meshheading:15813849-Adult,
pubmed-meshheading:15813849-Aged,
pubmed-meshheading:15813849-Bone Marrow Cells,
pubmed-meshheading:15813849-Child,
pubmed-meshheading:15813849-Child, Preschool,
pubmed-meshheading:15813849-Chromosomes, Human, Pair 21,
pubmed-meshheading:15813849-Chromosomes, Human, Pair 8,
pubmed-meshheading:15813849-Cytogenetic Analysis,
pubmed-meshheading:15813849-Disease-Free Survival,
pubmed-meshheading:15813849-Female,
pubmed-meshheading:15813849-Gene Deletion,
pubmed-meshheading:15813849-Genes, Tumor Suppressor,
pubmed-meshheading:15813849-Genetic Markers,
pubmed-meshheading:15813849-Humans,
pubmed-meshheading:15813849-Leukemia, Myeloid,
pubmed-meshheading:15813849-Male,
pubmed-meshheading:15813849-Middle Aged,
pubmed-meshheading:15813849-Survival Rate,
pubmed-meshheading:15813849-Translocation, Genetic
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Del (9q) AML: clinical and cytological characteristics and prognostic implications.
|
| pubmed:affiliation |
Leukaemia Research Fund Molecular Haematology Unit, John Radcliffe Hospital, Oxford, UK. andy.peniket@orh.nhs.uk
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|